Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 30, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Compare Different Preparations of Sisunatovir in Healthy Adult Participants.
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 14, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 26, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
Details : Sisunatovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Viruses.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 03, 2023
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : $155.0 million
Deal Type : Collaboration
Details : RV521 (sisunatovir) is an investigational orally administered fusion inhibitor designed to block RSV replication by inhibiting F-mediated fusion with the host cell. Sisunatovir is being evaluated for the potential treatment of RSV infection in pediatric ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $20.0 million
December 19, 2022
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : $155.0 million
Deal Type : Collaboration
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : $525.0 million
Deal Type : Acquisition
Pfizer Completes Acquisition of ReViral
Details : ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including RV521 (sisunatovir), an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 09, 2022
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : $525.0 million
Deal Type : Acquisition
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Pfizer Inc
Deal Size : $525.0 million
Deal Type : Acquisition
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
Details : Proposed acquisition strengthens Pfizer’s capabilities in infectious disease research and development with a promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 07, 2022
Lead Product(s) : Sisunatovir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Pfizer Inc
Deal Size : $525.0 million
Deal Type : Acquisition